Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]
In development
Reference number: GID-TA10745
Expected publication date:
Please note that following on from information received from the company this appraisal has now been scheduled back into the work programme. The appraisal is due to begin during mid-February 2027 when we will write to you about how you can get involved.